...in other models of melanoma. Abbott Laboratories and AbbVie Inc. market the PPARα agonist TriLipix fenofibric acid...
...a PPARα agonist, for hypercholesterolemia and hypertriglyceridemia. Aralez Pharmaceuticals Inc. markets the PPARα agonist Fibricor fenofibric acid...

...Tribute purchased U.S. rights from Sun to Fibricor fenofibric acid and its related authorized generic. Sun receives...

...adalimumab were up 13% to $3B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...

...adalimumab were up 16% to $2.8B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...

...adalimumab were up 12% to $2.6B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...

...the corresponding dose of simvastatin monotherapy. In territories outside the U.S., Abbott already markets Trilipix fenofibric acid...
...patients with severe hypertriglyceridemia, primary hyperlipidemia or mixed dyslipidemia. AbbVie Inc. (NYSE:ABBV, Chicago, Ill.) markets Trilipix...

...either fail completely or are inadequate." Brinton was an investigator for AbbVie Inc. 's Trilipix fenofibric acid...

...adalimumab were up 16% to $2.2B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid...

...in January 2011, AstraZeneca and partner Abbott Laboratories stopped development of dyslipidemia candidate Certriad rosuvastatin/ fenofibric acid...

...single doses of FP 250 led to significantly higher systemic exposure and plasma concentrations of fenofibric acid...